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APPLICATION OF THE KANO METHODOLOGY FOR EVALUATING 
MIGRAINE TREATMENT EXPECTATIONS AMONG PATIENTS TREATED 
BY NEUROLOGISTS IN SPAIN: THE MIGREXX STUDY
Matias J1, Nocea G2, Caloto T2
1Hospital Universitario San Carlos, Madrid, Spain; 2Merck Sharp & Dohme, SA, Madrid, Spain
OBJECTIVES: To classify the characteristics and properties of the pharmacological 
treatments among migraine patients treated by neurologists in Spain. Patients are 
becoming increasingly implicated in treatment decisions. Expectations in relation to 
therapy largely condition satisfaction with the results obtained. METHODS: Multi-
center, cross-sectional study in adult patients with at least one prescription of anti-
migraine drugs within the last year. The protocol was approved by the CREC of La 
Princesa University Hospital (Madrid). Sociodemographic, and clinical characteristics 
of patients, as well as questions regarding their expectations with regard to migraine 
treatments and evaluation of the importance of their attributes are documented. Using 
a treatment expectations questionnaire and applying Kano methodology, sixteen treat-
ment attributes were classiﬁ ed as: Must-be, One-dimensional, Attractive, Indifferent, 
Reverse or Questionable. Patients were required to give informed consent. RESULTS: 
68 neurologists included 174 patients diagnosed with migraine (mean age 39 years; 
75% women). None of the attributes were considered “Must-be”. The attributes 
considered by most patients to be “One-dimensional” were the absence of long-term 
adverse effects (55%), to allow work/study activities (50%), to allow social and family 
relationship (50%), achievement of symptoms relief (47%) and pain relief (44.3%). 
The attributes considered “Attractive” by most patients were: achievement of rapid 
symptoms and pain relief (54%), and achievement of total disappearance of the pain 
(53.4%). The attributes that led to a greater dissatisfaction were the occurrence of 
long-term adverse effects, not to allow work activity or studies and not to achieve 
pain relief. The three attributes that led to a greater satisfaction were achievement of 
total disappearance of the symptoms and the pain, and rapid pain relief. CONCLU-
SIONS: The expectations regarding a medical treatment signiﬁ cantly inﬂ uence the sat-
isfaction reached with the outcome of such treatment. a better knowledge of patient’s 
expectations can lead to a greater satisfaction associated with treatment outcomes.
PND48
MODIFIED LAST OBSERVATION CARRIED FORWARD IS A SUPERIOR 
METHOD OF IMPUTATION
DeGryse R, Lei X, Fainaru I, Turkel C
Allergan, Inc., Irvine, CA, USA
OBJECTIVES: To compare imputation methods using PREEMPT (Phase III REsearch 
Evaluating Migraine Prophylaxis Therapy) clinical data. METHODS: Data were 
analyzed from two phase 3 studies of onabotulinumtoxinA in chronic migraine 
(ICHD-II migraine and ≥15 headache days/month). Each study included a 24-week, 
randomized, double-blind, parallel-group, placebo-controlled phase, followed by a 
32-week, open-label onabotulinumtoxinA treatment phase. The prespeciﬁ ed method 
of imputation of missing data (ie, <20 days of diary data in a 28-day period) was 
modiﬁ ed last observation carried forward (mLOCF), which estimated missing data by 
iteratively multiplying the subject’s most recent count by the subsequent average 
change rate across treatments. We compared mLOCF with last observation carried 
forward (LOCF), baseline observation carried forward (BOCF), mLOCF within-
treatment (mLOCFw), and observed data (without imputation). Simulations to predict 
known data were analyzed using mLOCF, LOCF, and BOCF. RESULTS: 1384 adults 
were randomized (PREEMPT1: onabotulinumtoxinA [n = 341], placebo [n = 338]; 
PREEMPT2: onabotulinumtoxinA [n = 347], placebo [n = 358]). 1026 (74%) of the 
subjects had no missing monthly counts during the double-blind phase (PREEMPT1: 
onabotulinumtoxinA [n = 242], placebo [n = 248]; PREEMPT2: onabotulinumtoxinA 
[n = 258], placebo [n = 278]). Each imputation method (mLOCF, LOCF, BOCF, 
mLOCFw) and observed data generated a similar statistically signiﬁ cant between-
group difference for the primary efﬁ cacy endpoint of headache-day counts at Week 
24 in PREEMPT2 (P < 0.001). Similar results were observed within PREEMPT1 (P < 
0.02). Compared to LOCF and BOCF, mLOCF was superior at predicting known 
values of headache-day counts in simulations that randomly set observed scores to 
missing, as demonstrated by least-squared errors of imputed minus actual counts. 
CONCLUSIONS: PREEMPT treatment differences were similar (and statistically sig-
niﬁ cant) using each imputation method, likely due to low dropout rates within each 
treatment group. Compared to LOCF and BOCF, mLOCF was superior at predicting 
known data. 
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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META-ANALYSIS OF PARTIALLY HYDROLYZED 100%-WHEY FORMULA 
VERSUS EXTENSIVELY HYDROLYZED FORMULAS IN THE PREVENTION 
OF ATOPIC DERMATITIS
Iskedjian M1, Szajewska H2, Spieldenner J3, Farah B4, Berbari J4, Navarro V5
1PharmIdeas Research and Consulting Inc., Oakville, ON, Canada; 2Medical University of 
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OBJECTIVES: The incidence rates of atopic dermatitis (AD) and relative risks (RR) 
associated to a brand of partially hydrolyzed 100% whey formula manufactured by 
Nestlé (PHF-W) and to extensively hydrolyzed formulas (EHF-Whey or Casein) were 
reported for the prevention of AD in infants who are not exclusively breastfed. 
METHODS: Szajewska et al. had previously undertaken a meta-analysis determining 
the incidence rates and RRs of PHF-W compared to cow’s milk formula (CMF) and 
EHF but details were not for provided for PHF-W vs. EHF. This analysis sheds light 
on the latter comparisons and extends the analyses to 3-month cycles from birth to 
36-months of age. Included were any relevant randomized controlled trials comparing 
the use of PHF-W with CMF or EHF for the prevention of allergies. The primary 
outcomes of interest were the incidence, cumulative incidence and period prevalence 
of any allergic manifestations and AD in particular. Of 84 retrieved citations, 15 
studies were included for analysis of which 6 studies pertained to PHF-W vs. EHF. 
All efﬁ cacy data were converted into inputs for a spreadsheet decision-analytic eco-
nomic model based on 3-month cycles by applying weights derived from the Szajewska 
et al. meta-analysis and calculating them at 3-month intervals for input into an eco-
nomic model. RESULTS: The analysis sample included 557, 559 and 580 patients for 
PHF-W, EHF-Whey and EHF-Casein, respectively. a RR of 0.75 [0.54,1.05] at 0–12 
months and 0.80 [0.63,1.02] at 0–36 months was obtained for PHF-W vs. EHF-Whey 
while a RR of 1.06 [0.74,1.53] at 0–12 months and 1.13 [0.87,1.47] at 0–36 months 
was determined for PHF-W vs. EHF-Casein. All efﬁ cacy data were adapted into 
3-month indicators. CONCLUSIONS: It appears that the efﬁ cacy of PHF-W falls 
within the range of the other two extensively hydrolyzed formulas. 
SENSORY SYSTEMS DISORDERS – Cost Studies
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USE OF INCREASED DOSAGES OF BIOLOGICS IN PLAQUE PSORIASIS 
AND POTENTIAL SAVINGS BY TREATING HIGH-DOSE PATIENTS WITH 
USTEKINUMAB INSTEAD—A BUDGET IMPACT MODEL
Klesse M, Wolbring F
Janssen-Cilag GmbH, Neuss, Germany
OBJECTIVES: Evaluation of real-life dosing of biologics in plaque psoriasis in 
Germany and the potential savings by treating patients with ustekinumab instead of 
using higher doses of TNF-alpha-inhibitors. METHODS: Based on an online survey 
among 100 dermatologists (DocCheck Medical Services, December 2009) the use of 
biologics and their dosing distribution for the treatment of plaque psoriasis was evalu-
ated. The proportion of patients receiving maintenance dosages according to label and 
those receiving a higher dose were evaluated for each biologic separately. a budget 
impact model was created estimating potential savings by treating patients with 
ustekinumab according to label (45 mg in patients ≤100 kg body weight and 90 mg 
in patients >100 kg body weight) instead of high dose TNF-alpha-inhibitors in terms 
of annual medication costs. In this model, costs of the current usage pattern of biolog-
ics were estimated using German pharmacy prices (source: Lauer-Taxe, version June 
1, 2010, most economical pack size). RESULTS: In most cases biologic treatments are 
used according to the respective labels. In some instances, deviating dosages are used: 
14% of adalimumab-treated patients receive an increased dosage of 40 mg every week 
or 80 mg eow, and more than 15% of etanercept-treated patients receive 50 mg twice 
weekly or another deviating dosage as maintenance therapy. 27% of inﬂ iximab-
treated patients receive maintenance injections more frequently than every 8 weeks or 
receive an increased dosage per injection. In Germany, assuming 80% of those high-
dose-TNF-alpha-inhibitor-treated patients are treated with ustekinumab instead, this 
would result in savings of approximately c18 million per year. If induction costs of 
ustekinumab are considered additionally, still c13 million could be saved within one 
year. CONCLUSIONS: Using ustekinumab instead of high dosages of TNF-alpha-
inhibitors for treatment of plaque psoriasis can generate signiﬁ cant savings in medica-
tion costs in Germany.
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OBJECTIVES: Some research has shown that Hand Eczema is often work-related, 
widespread, potentially disabling and costly disease, but misdiagnosed and mistreated. 
Severe Chronic Hand Eczema (CHE) can be particularly burdensome. We aimed to 
assess prevalence, costs and HRQoL in patients with severe CHE. METHODS: A 
naturalistic, multicentre, epidemiologic and cost-of-illness study is being conducted in 
14 Italian dermatological centers. HE patients aged ≥18 years are being enrolled 
through a 6-month period. The following data are being collected: socio-demographic, 
clinical (severity, chronicity and responsiveness to treatment with topical potent cor-
ticosteroids) and, among chronic, severe and refractory patients, data on HRQol 
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(EQ-5D and the condition speciﬁ c Dermatitis-Life-Quality-Index (DLQI)), direct and 
indirect costs, from the societal perspective. RESULTS: A preliminary sample of 305 
patients (mean age + SD = 41.4 + 14.9, 38.2% male) were enrolled. Two hundred 
ﬁ fty ﬁ ve patients (83.6%) had CHE and of these the 27.8% were severe. Overall, 
20.0% of the enrolled patients were chronic, severe and refractory to therapy. DLQI 
mean + SD sum score was 10.38 + 5.98. With EQ-5D 92.7% of patients reported 
moderate or severe pain/discomfort, 70.9% problems with usual activities, 58.2% 
anxiety/depression and 40% problems with self-care. VAS mean + SD = 61.96 + 21.48. 
On average hospitalization cost c87.90/patient-month, travels due to CHE cost 
c69.54/patient-month, specialist visit costs c52.81/patient-month, other products 
(gloves, gauze bandage, vacuum cleaner, cosmetics) costs c35.70/patient-month, diag-
nostic exam costs c20.77/patient-month, non pharmacological therapy (emollients, 
galenic products, soap, UV-ray) cost c15.65/patient-month and pharmacological 
therapy cost c9.22/patient-month. Patients lost a mean + SD 4.35 + 8.68 workdays/
patient-month for reasons attributable to their condition. CONCLUSIONS: most of 
the patients in the Italian centers of dermatology have CHE and a ﬁ fth are severe and 
refractory to therapy. Patients with severe CHE and refractoriness to therapy have 
poor HRQoL and high costs. a correct diagnosis and treatment is necessary to efﬁ -
ciently manage this condition.
PSS4
COST-OF-ILLNESS IN PATIENTS WITH CHRONIC HAND ECZEMA: 
RESULTS FROM A MULTI-CENTRE STUDY IN GERMANY
Augustin M1, Purwins S1, Diepgen T2, Posthumus J3, Kuessner D3
1University Clinics of Hamburg, Hamburg, Germany; 2University Heidelberg, Heidelberg, 
Germany; 3Basilea Pharmaceutica, Basel, Switzerland
OBJECTIVES: It is assumed broadly that the costs caused by chronic hand eczema 
(CHE) are signiﬁ cant. However, there is a lack of cost-of-illness studies on CHE. The 
objective of this study is, therefore, to determine the direct and indirect costs of chronic 
hand eczema under routine conditions overall and in different treatment stages in 
Germany. METHODS: The survey was conducted in 24 outpatient practices and 
clinics across Germany. Patients with CHE refractory to potent topical treatments and 
insured by statutory health insurances were eligible. Patient characteristics and 
resource use were directly gathered from patients and physicians. Costs were evaluated 
from the societal perspective. Four treatment stages were deﬁ ned: only topical treat-
ments (stage I), additionally photo therapy (II), systemic therapy (III) and inpatient 
treatment (IV). Bivariate associations between costs and treatment stage were assessed. 
RESULTS: A total of 223 CHE patients enrolled in the study. The yearly direct and 
indirect costs per patient are c1742 (SE: c139) and c386 (c83), respectively. a total 
of 63.2% of patients were treated only with topical treatments; additionally 15.7% 
with photo therapy, 11.7% with systemic treatments. a total 9.4% of all patients were 
admitted to hospitals. The total costs increase with treatment stage I-IV (P < 0.001): 
c1044 (c85), c2307 (c145), c2697 (c461) and c8407 (c991), respectively. Accord-
ingly, costs also correlated with clinical severity. CONCLUSIONS: CHE patients 
refractory to topical steroids incur marked costs to the society. The costs are increasing 
disproportionately with escalating treatment stages, especially in patients admitted to 
hospitals. Hence, new and innovative treatments may help to reduce the societal costs 
of CHE.
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COST OF GLAUCOMA IN THE UNITED KINGDOM ACCORDING TO 
THE UK GPRD
Salmon J1, Lafuma A2, Robert J2, Berdeaux G3
1Oxford Eye Hospital, Oxford, UK; 2CEMKA-EVAL, Bourg la Reine, France; 3Alcon France, 
Rueil-Malmaison, France
OBJECTIVES: The objective of this analysis was to estimate the total budget dedicated 
to glaucoma care according to the UKGPRD and to identify factors associated with 
high costs. METHODS: Data were extracted on patients treated on the National 
Health Service with a diagnosis of ocular hypertension or glaucoma, or treated with 
topical intraocular lowering treatment, surgery or laser for glaucoma. The budget was 
estimated from resources consumed in 2008 and included glaucoma drugs, laser, 
surgery, hospitalization, specialist and general practitioner (GP) visits. In-patient 
resources were estimated from the Hospital Episode Statistics. Results were expressed 
in GBP, 2008. Factors associated with high cost were identiﬁ ed using linear stepwise 
regression. National extrapolation was performed according to the relative size of the 
GPRD to the UK general populations. RESULTS: Details of 33,441 patients were 
extracted, which suggests that about 510,000 patients were treated in the NHS in UK 
in 2008. The Mean age was 74.2 years, and 47.3% were male. The initial diagnosis 
was made at 67.8 years. Older patients, longer time since diagnosis, a higher number 
of previous treatments, a higher number of treatment switches in the previous one 
year period and use of laser/surgery were associated with a higher annual cost. Spend-
ing varied little between regions. Annual drug spending was £91.2 million on in-
patient care, £4.4 million on drug prescription renewal (not speciﬁ c to the glaucoma 
drug). Visits to the GP cost £34.8 million and visits to the eye specialist was >£54.0 
million although the latter ﬁ gure is likely to be an under estimate (GPRD underre-
ported eye doctor care). CONCLUSIONS: The 2008 expenditures to care for glau-
coma were >£185 million with no regional differences. Three factors were strongly 
associated with high costs: time since diagnosis, treatment changes, and rescue treat-
ment. This analysis suggests that longer treatment persistence is likely to be associated 
with cost saving.
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COST OF ILLNESS OF PSORIASIS—A 1-MONTH PROSPECTIVE STUDY 
IN SOUTHERN SWEDEN
Ghatnekar O1, Ljungberg A2, Lundqvist T2, Svensson Å3, Wirestrand LE4
1The Swedish Institute for Health Economics, Lund, Skåne, Sweden; 2Abbott Scandinavia AB, 
Solna, Sweden; 3University of Lund, Malmö, Sweden; 4Kristianstad Hospital, Kristianstad, 
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OBJECTIVES: Published cost-of-illness studies of psoriasis in Sweden are not avail-
able. This study estimates the societal cost of psoriasis care in a deﬁ ned Swedish patient 
population. METHODS: A prevalence-based prospective recruitment of patients visit-
ing two dermatology clinics in Sweden between September and December 2009 was 
performed. Patients collected resource utilization of health care contacts, treatment, 
travelling distance and time, and productivity loss (human capital approach) during 
1 month (Swedish unit prices, 2009). RESULTS: A total of 164 patients (49% males) 
were included; average age 52, 76% plaque psoriasis with PASI 5.7, DLQI 7.7 and 
EQ-5D utility weight 0.71. The mean total cost per patient-month was c994. Main 
cost drivers were outpatient visits (OP) and light therapy (49%), biological drugs 
(20%) and productivity loss (22%). When patients were stratiﬁ ed according to treat-
ment strategy, total costs (fraction of patients) for topical treatment only (TT; 34%) 
was c369, light therapy (LT; 24%) c1274, traditional systemic treatment (TST; 26%) 
c1085 and biological systemic treatment (BST; 16%) c1709 per patient-month. Main 
cost drivers in each treatment strategy were: OP (56%) in TT, OP (78%) in LT, 
productivity loss (40%) in TST and biological drugs (71%) in BST. There was no 
clear relationship between clinical (PASI) or subjective (DLQI) severity estimations 
and costs. CONCLUSIONS: In this study the cost-of-illness for a psoriasis patient 
amounts to almost c1000/month, with great variation depending on treatment strat-
egy. Despite the 1200 difference in drug cost for TST vs. BST, total cost per month 
differed by c600 because of offsets from improved productivity and reductions in OP 
and topical treatment. As expected, biologically treated patients had higher costs but 
lower severity probably due to the treatment effectiveness. The relationship between 
costs and severity is complex, probably due to the selected study period and differences 
in effect between strategies.
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THE ECONOMIC COST OF TREATING PATIENTS WITH AGE-RELATED 
MACULAR DEGENERATION IN SPAIN
Darba J1, Kaskens L2
1Universitat de Barcelona, Barcelona, Spain; 2BCN Health, Barcelona, Spain
OBJECTIVES: Wet macular degeneration associated with age (wet-AMD) is the 
leading cause of legal blindness in Spain in people over 55. The aim of this study is 
to determine health care resource utilization and mean costs per patient with wet-AMD 
in 2009. METHODS: A micro-costing analyses was performed to estimate direct 
medical costs of patients with wet-AMD. Patient level data was obtained from differ-
ent public hospitals in Spain and ophthalmologists were surveyed with a semi-struc-
tured questionnaire to obtain treatment patterns. Inpatient costs were considered from 
the perspective of the public health care system. Treatments under study were pegap-
tanib, verteporﬁ n, ramibizumab and bavacizumab. Although bevacizumab in Spain is 
not approved for wet-AMD, it was used off-label in the hospital. Direct medical costs 
considered were drug costs, administration cost, doctors’ visits, nurse time, ophthal-
mologist time, anaesthetics, ambulant hospital care, external consultation, surgery and 
treatment of adverse effects. All costs are referred to 2009. RESULTS: Mean cost per 
patient treated with wet-AMD represented the following cost for the public health 
care system: c7290 for pegaptanib, c5810c for verteporﬁ n, c8650 for ramibizumab 
and c3110 for bevacizumab. We also estimated that in Spain 180,000 people over 50 
years have wet-AMD in 2009. CONCLUSIONS: Pharmacological treatments for 
wet-AMD are photo dynamic therapy with verteporﬁ n, pegaptanib, verteporﬁ n and 
ramibizumab, with the last one having the highest medical costs. The aging of the 
population and development of new drugs will probably increase the future economic 
impact of AMD, which remains a major health care burden.
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PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COST IN 
GERMANY
Lorenz K1, Wolfram C1, Claus V2, Plesnila-Frank C2, Verboven Y3, Pfeiffer N1
1Universitätsmedizin Mainz, Mainz, Germany; 2IMS Health, München, Germany; 3Alcon 
Research Ltd., Puurs, Belgium
OBJECTIVES: To describe total costs and factors predicting cost in Germany for 
glaucoma disease states: ocular hypertension (OHT), and early (EARLY), moderate 
(MOD) and advanced (ADV) glaucoma. METHODS: A 5-year retrospective analysis 
collected health care utilization, clinical parameters, treatment(s) used and reasons for 
treatment change. Disease states deﬁ ned by the European Glaucoma Society were 
applied. Costs for health care resources were based upon the German EBM/OPS code 
for ambulatory visits/procedures, diagnosis-related groups for hospital procedures and 
the Rote Liste for medication. Factors predicting cost were identiﬁ ed using stepwise 
backward multiple linear regression, entry criterion a = 0.2. RESULTS: A total of 154 
patients (27 OHT, 43 EARLY, 35 MOD, 49 ADV) were enrolled from 15 centers 
across 5 German regions. Average age was 67 ± 11 and 57% were female. Number 
of years since diagnosis was 9.0 ± 5.7, 8.7 ± 4.6, 8.7 ± 4.1 and 13.2 ± 8.3 years for 
OHT, EARLY, MOD and ADV, respectively. Total costs, for patients with OHT, 
EARLY, MOD or ADV, were c226 ± 117, c423 ± 647, c493 ± 385, and c808 ± 877, 
respectively. Most costs were due to medication (c121 ± 99, c217 ± 150, c245 ± 161, 
c340 ± 193) and hospital interventions (c32 ± 101, c115 ± 538, c154 ± 285, c367 ± 
